• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

Layoffs

Quote








anonymous said:
Sigh. How many were cut from eye division?
Click to expand...

If you include cutting the contract salesforce they slaughtered about two thirds. Three reps in a territory to one rep, about cut the managers in half, same with the RDs (six to two plus one for inside sales), took out inside sales people too, and rumor is they hit some home office folks as well. The cuts were massive. Abbvie knows it's about to hit the fan with all the LOEs.
 




anonymous said:
If you include cutting the contract salesforce they slaughtered about two thirds. Three reps in a territory to one rep, about cut the managers in half, same with the RDs (six to two plus one for inside sales), took out inside sales people too, and rumor is they hit some home office folks as well. The cuts were massive. Abbvie knows it's about to hit the fan with all the LOEs.
Click to expand...
Yeah it was brutal.
 
















anonymous said:
Word on the Street 50%? Please someone confirm or deny. Which is next? Derm? WH? GIC?
Click to expand...
Pretty sure CNS, 1 vraylar rep to every 3 doctors....and the Migraine will be next....Just too much overlap with not enough drug...may not happen until after the indication launch for CNS but that will be greeted with yeah so what...always have used it that way...etc. Good luck Pharma is dying...Spent a long long long long time in it and it was a good ride, but what it has become particularly with the pushing of programs and activities ....never be the same
 




Top Bottom
Back
Quote